National Cell and Gene Manufacturing Blueprint

With the rapid and ongoing global growth of cell and gene (C&G) products, there is an opportunity for Australia to be a regional C&G hub. This report was commissioned by AusBiotech and delivered by Biointelect to build on 2021’s Regenerative Medicines Consortium Programme and produce a National Blueprint for the strategic growth and development of […]

Bringing Patient Centricity to Life in Australian Healthcare

The current healthcare environment in Australia offers various opportunities for stakeholders, including patients, to engage with the health system and government in reform efforts. These opportunities arise from factors such as increased awareness of the importance of efficient approval processes for medicines and vaccines due to the COVID-19 pandemic, ongoing reviews of health technology assessment […]

Roundtable: Response and resilience of the Australian life sciences sector

As the world emerges from the pandemic, it is critical to reflect on what has been learned and how to make strategic and sustainable investments for the future. Australia must identify and prioritise local investments, co-designed with stakeholders, and collaborating with the global life sciences sector.  Effective investments have the potential to deliver benefits across […]

Strengthening Australia’s Approach to Horizon Scanning for New Therapies

Horizon scanning is a process or system which seeks to systematically identify and assess the potential impact of new and emerging health technologies on patients and other healthcare system stakeholders.  This facilitates proactive planning for the arrival of new health technologies. BMS convened the Shaping Healthcare Together Roundtable, under the Broadening the Evidence project, online […]

Submission to the PBAC on the Base Case Discount Rate

Discount rates reflect how society values future outcomes compared to present outcomes. When applied to medicines, inappropriately high discount rates disadvantage treatments which have longer term health benefits, such as preventative or curative treatments, disproportionately discriminating against patients who could benefit from treatments where the benefits are realised over a longer period of time. As […]

Fighting Super Bugs

In 2019, Biointelect and MTPConnect convened a multi-disciplinary workshop to bring together key stakeholders in the sector (Regulators, state / territory governments, academia, industry) to discuss the threat of antimicrobial resistance and what could be achieved in collaboration.  This workshop led to the creation of the report ‘Fighting Superbugs: A Report on the Inaugural Meeting […]

White Paper on Precision Medicine in Australia

In 2019 MTPConnect commissioned Biointelect to facilitate a Round Table bringing together stakeholders in the sector to discuss the key issues surrounding technology, regulation and reimbursement, commercialisation, and implementation.  This was done so MTPConnect can understand how to better support the sector in implementing precision medicine into the Australian healthcare system and contribute as a […]

Contemporary issues in valuing new oncology medicines: Do we need a new model?

In 2019 Biointelect hosted its second annual medicines policy symposium, this report summarises the main points of the presentation discussing this topic. The main discussions being the challenges of valuation of new oncology medicines, whether oncology submissions are optimal for assessment of value, what is to be learnt from the international discussion on valuation and […]

Six Months in a Leaky Boat

Six Months in a Leaky Boat featured in 2019 at the ARCS (Association of Regulatory and Clinical Scientists) conference, it explored the reasons for uncertainty contributing to rejections of reimbursement submissions at Australia’s Pharmaceutical Benefit Advisory Committee (the PBAC).  Companies spend a considerable amount of time and money developing submissions for the PBAC, the evaluation […]